Nowe doustne antykoagulanty w leczeniu żylnej choroby zakrzepowo-zatorowej – przypis do nowych standardów Europejskiego Towarzystwa Kardiologicznego dotyczących migotania przedsionków (A.D. 2012) Przypis
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
wrz 30, 2012
##plugins.themes.bootstrap3.article.main##
Abstrakt
Brak
##plugins.themes.bootstrap3.article.details##
Jak cytować
Pruszczyk, P. (2012). Nowe doustne antykoagulanty w leczeniu żylnej choroby zakrzepowo-zatorowej – przypis do nowych standardów Europejskiego Towarzystwa Kardiologicznego dotyczących migotania przedsionków (A.D. 2012) . Medycyna Faktów , 5(3(16), 48-51. Pobrano z https://journalsmededu.pl/index.php/jebm/article/view/2455
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. Camm A.J., Lip G.Y., De Caterina R., Savelieva I., Atar D., Hohnloser S.H. et al.: 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: An update of the 2010 ESC Guidelines for the management of atrial fibrillation * Developed with the special contribution of the European Heart Rhythm Association. Eur. Heart J. 2012 Aug 24. [Epub ahead of print].
2. Eriksson B.I., Borris L.C., Friedman R.J. et al.: Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N. Engl. J. Med. 2008; 358: 2765-277.
3. The EINSTEIN Investigator: Oral rivaroxaban for symptomatic venous thromboembolism. N. Engl. J. Med. 2010 Dec 23; 363(26): 2499-2510.
4. EINSTEIN–PE Investigators: Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N. Engl. J. Med. 2012 Apr 5; 366(14): 1287-97. Epub 2012 Mar 26.
5. Lassen M.R., Raskob G.E., Gallus A. et al.: Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N. Engl. J. Med. 2009; 361: 594-604.
6. Efficacy and Safety Study of Apixaban for Extended Treatment of Deep Vein Thrombosis or Pulmonary Embolism [online].
7. Eriksson B.I., Dahl O.E., Rosencher N., Kurth A.A., van Dijk C.N., Frostick S.P., Kälebo P., Christiansen A.V., Hantel S., Hettiarachchi R., Schnee J., Büller H.R.; RE-MODEL Study Group: Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J. Thromb. Haemost. 2007 Nov; 5(11): 2178-85.
8. Eriksson B.I., Dahl O.E., Rosencher N. et al.: Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 2007; 370: 949-956.
9. Ginsberg J.S., Davidson B.L., Comp P.C. et al.: Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J. Arthroplasty 2009; 24: 1.
10. Schulman S., Kearon C., Kakkar A.K., Mismetti P., Schellong S., Eriksson H., Baanstra D., Schnee J., Goldhaber S.Z.: Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism. N. Engl. J. Med. 2009; 361: 2342-2352.
2. Eriksson B.I., Borris L.C., Friedman R.J. et al.: Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N. Engl. J. Med. 2008; 358: 2765-277.
3. The EINSTEIN Investigator: Oral rivaroxaban for symptomatic venous thromboembolism. N. Engl. J. Med. 2010 Dec 23; 363(26): 2499-2510.
4. EINSTEIN–PE Investigators: Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N. Engl. J. Med. 2012 Apr 5; 366(14): 1287-97. Epub 2012 Mar 26.
5. Lassen M.R., Raskob G.E., Gallus A. et al.: Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N. Engl. J. Med. 2009; 361: 594-604.
6. Efficacy and Safety Study of Apixaban for Extended Treatment of Deep Vein Thrombosis or Pulmonary Embolism [online].
7. Eriksson B.I., Dahl O.E., Rosencher N., Kurth A.A., van Dijk C.N., Frostick S.P., Kälebo P., Christiansen A.V., Hantel S., Hettiarachchi R., Schnee J., Büller H.R.; RE-MODEL Study Group: Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J. Thromb. Haemost. 2007 Nov; 5(11): 2178-85.
8. Eriksson B.I., Dahl O.E., Rosencher N. et al.: Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 2007; 370: 949-956.
9. Ginsberg J.S., Davidson B.L., Comp P.C. et al.: Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J. Arthroplasty 2009; 24: 1.
10. Schulman S., Kearon C., Kakkar A.K., Mismetti P., Schellong S., Eriksson H., Baanstra D., Schnee J., Goldhaber S.Z.: Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism. N. Engl. J. Med. 2009; 361: 2342-2352.